DUI News: FDA Requests Label Change for All Sleep Disorder Drug Products

FDA Requests Label Change for All Sleep Disorder Drug Products: " FDA Home Page Search FDA Site FDA A-Z Index Contact FDA FDA News FOR IMMEDIATE RELEASE P07-45 March 14, 2007 Media Inquiries: Sandy Walsh Kimberly Rawlings 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Requests Label Change for All Sleep Disorder Drug Products The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving. Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event. 'There are a number of prescription sleep aids available that are well-tolerated and effective for many people,' said Steven Galson, M.D., MPH, director of FDA’s Center for Drug Evaluation and Research. 'However, after reviewing the available post-marketing adverse event information for these products, FDA concluded that labeling changes are necessary to inform health care providers and consumers about risks.' In December 2006, FDA sent letters to manufacturers of products approved for the treatment of sleep disorders requesting that the whole class of drugs revise product labeling to include warnings about the following potential adverse events: Anaphylaxis (severe allergic reaction) and angioedema (severe facial swelling), which can occur as early as the first time the product is taken. Complex sleep-related behaviors which may include sleep-driving, making phone calls, and "